<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22122" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gaucher Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stone</surname>
            <given-names>William L.</given-names>
          </name>
          <aff>East Tennessee State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basit</surname>
            <given-names>Hajira</given-names>
          </name>
          <aff>Brookdale University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukkamalla</surname>
            <given-names>Shiva Kumar R.</given-names>
          </name>
          <aff>Presbyterian Healthcare Services</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Master</surname>
            <given-names>Samip R.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>William Stone declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hajira Basit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samip Master declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22122.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gaucher disease, the most prevalent lysosomal storage disorder, presents with an elevated incidence among Ashkenazi Jews. It is an autosomal recessive inborn error of metabolism characterized by the toxic accumulation of glucocerebroside lipids within multiple organs. Gaucher disease results from mutations in the <italic toggle="yes">GBA1</italic> gene, leading to deficient glucocerebrosidase activity within lysosomes. Clinical manifestations, including hepatosplenomegaly, pancytopenia, osteoporosis, and avascular necrosis, vary in severity depending on the disease type. This activity comprehensively examines the assessment and management of Gaucher disease while emphasizing the pivotal role of the interprofessional team in collaborating and delivering well-coordinated care to improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen individuals at risk for Gaucher disease, including family members of affected individuals, using appropriate diagnostic tools and criteria.</p></list-item><list-item><p>Assess the clinical status and disease progression of individuals with Gaucher disease through regular physical examinations, laboratory testing, and imaging studies.</p></list-item><list-item><p>Implement evidence-based treatment protocols for Gaucher disease, including enzyme replacement therapy, substrate reduction therapy, and supportive care measures.</p></list-item><list-item><p>Collaborate with&#x000a0;an interprofessional team to provide multidisciplinary care for individuals with Gaucher disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22122&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22122">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22122.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gaucher disease (pronounced as GO-SHEY) is an autosomal recessive inborn error of metabolism caused by mutations in the glucocerebrosidase (<italic toggle="yes">GBA1</italic>) gene<xref ref-type="bibr" rid="article-22122.r1">[1]</xref>. GBA1 is an enzyme that cleaves the beta-glucosidic linkage of glucocerebroside lipids.&#x000a0;</p>
        <p>Gaucher disease is a poignant testament to the intricate interplay between genetics, biochemistry, and clinical medicine. Named after the French physician Philippe Charles Ernest Gaucher, who first described it in 1882, this inherited metabolic disorder is characterized by the accumulation of lipids, specifically glucocerebroside, within various tissues and organs throughout the body. Gaucher disease can manifest in a spectrum of clinical presentations, with mild to severe symptoms affecting individuals of diverse ages and backgrounds.</p>
        <p>Inborn errors of metabolism&#x000a0;are particularly relevant in pediatrics since their presentation is very often (but not always) in the neonatal period of infancy. There are&#x000a0;5 known types of Gaucher disease: type 1, type 2, type 3, perinatal lethal, and cardiovascular. The perinatal lethal form is the most severe, and its complications can begin before birth or in early infancy.</p>
        <p>Knowing the major manifestations of any&#x000a0;inborn error of metabolism&#x000a0;is the key to making a diagnosis. Inborn errors of metabolism&#x000a0;primarily result from the lack (or insufficient levels) of specific enzymes needed: (1) to convert fat or carbohydrates to energy or (2) to break down amino acids or other metabolites, allowing them to accumulate and become toxic if not treated. Gaucher disease is a &#x0201c;toxic accumulation&#x0201d;&#x000a0;inborn error of metabolism&#x000a0;due to the accumulation of glucocerebroside lipids. Toxic accumulation&#x000a0;inborn errors of metabolism&#x000a0;fall into&#x000a0;3 major categories: localized toxicity, circulating toxicity, or a combination of both. Gaucher disease is an example of localized toxicity.</p>
      </sec>
      <sec id="article-22122.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The underlying cause of all forms of Gaucher disease is mutations in the <italic toggle="yes">GBA1</italic> gene, resulting in a lysosomal deficiency of glucocerebrosidase activity. All forms of Gaucher disease lead to the toxic accumulation of glucocerebroside lipids, primarily in the liver, spleen, and bone marrow. A glucocerebroside is composed of a glucose molecule linked to the oxygen atom on carbon atom 1 of the sphingosine moiety of ceramide.</p>
        <p>All forms of Gaucher disease are also classified as lysosomal storage disorders. There are at least 40 other lysosomal storage disorders, including mucopolysaccharidosis, Tay-Sachs disease, and Fabry disease<xref ref-type="bibr" rid="article-22122.r2">[2]</xref>. All lysosomal storage disorders tend to worsen over time; in other words, they are progressive. Lysosomes are spherical intracellular organelles where many lipids and macromolecules are delivered for degradation by hydrolytic enzymes. Lysosomes are abundant in macrophages. The lysosomes in the macrophages of patients with Gaucher disease become progressively enlarged and filled with undigested glucocerebroside. The lysosomes can eventually be filled with undigested lipids that resemble "crumpled tissue paper" when visualized by electron microscopy. Without appropriate treatment, the liver can expand 2-fold to 3-fold its normal size and the spleen by 15-fold.</p>
        <p>Despite knowing the precise genetic causes of most forms of Gaucher disease, the exact cause remains unknown. Patients with the same mutation can have very different signs and symptoms. It is also possible for patients with similar signs and symptoms to have very different genetic mutations. Environmental factors, as well as an individual's particular genetic makeup, most likely influence the&#x000a0;phenotypic expression of Gaucher disease.</p>
      </sec>
      <sec id="article-22122.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Gaucher disease is the most common autosomal recessive disease in the Ashkenazi (Eastern European) Jewish population, with a carrier frequency of 6% compared to 0.7% to 0.8% of the non-Jewish population. Cystic fibrosis (4% carrier frequency) and Tay-Sachs Disease (3.7% carrier frequency) are also common in the Ashkenazi population.<xref ref-type="bibr" rid="article-22122.r3">[3]</xref></p>
        <p>The most common form of Gaucher disease is type 1, which has a very variable phenotype ranging from early childhood symptoms to no symptoms throughout life but typically does not have a neurological component. In contrast to type 1, types 2 and 3 are rare and affect the central nervous system. Both type 2 and the perinatal lethal type usually result in neonatal death, whereas type 3 results in mid to early adulthood death.</p>
      </sec>
      <sec id="article-22122.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The signs and symptoms of Gaucher disease can be classified into visceral, hematologic, skeletal, and metabolic components.&#x000a0;The visceral components include an enlarged liver and spleen (hepatosplenomegaly).</p>
        <p>Hematological components can include thrombocytopenia, anemia, and leukopenia. Cerebroside accumulation in the bone marrow is thought to decrease platelet production, resulting in low platelet count. Similarly, cerebroside accumulation in the spleen is thought to result in an excessive breakdown of red blood cells, resulting in anemia and more active removal of white blood cells (WBC), resulting in a low WBC count.&#x000a0;The rapid and premature destruction of blood cells can increase the risk of bleeding and infections.</p>
        <p>The skeletal components can include bone crisis, the death of bone cells (called avascular necrosis or osteonecrosis), a low bone density compared to normal peak density, pathological bone fracture, and Erlenmeyer flask deformity. Much of these skeletal abnormalities are attributed to the buildup of glucocerebroside-laden macrophages in the bone marrow, where they restrict blood flow and the delivery of nutrients and oxygen, which can result in intense pain, bone cell necrosis, low bone density, and growth abnormalities.</p>
        <p>Metabolic disturbances, especially disorders of nutrition and glucose metabolism, are observed in&#x000a0;pediatric and adult patients with Gaucher disease.&#x000a0;Abnormal body weight and related metabolic disturbances are common issues.&#x000a0;An increased focus on detecting metabolic disturbances, especially nutritional status disorders, insulin resistance, and lipid alterations, is strongly recommended to optimize&#x000a0;care management in affected patients.<xref ref-type="bibr" rid="article-22122.r4">[4]</xref></p>
      </sec>
      <sec id="article-22122.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Classic glycolipid-laden macrophages are found in liver biopsy and bone marrow samples.</p>
        <p>Liver biopsy samples typically reveal glycolipid-laden Gaucher cells evident in the sinusoids. Still, the hepatocytes do not manifest overt glycolipid storage&#x000a0;because of biliary excretion of glucocerebroside and because the mononuclear phagocytes typically handle exogenous glycolipid turnover. As&#x000a0;hepatocytes are spared, there is a very low incidence of liver failure in individuals with Gaucher disease.</p>
        <p>The pathologic hallmark of Gaucher disease is Gaucher cells in the macrophage-monocyte system typically found in the bone marrow. These cells&#x000a0;have a characteristic wrinkled-paper appearance, resulting from intracytoplasmic substrate deposition, and stain positive with periodic acid&#x02013;Schiff. Histologic evaluation should&#x000a0;not be used as a primary diagnostic tool.</p>
      </sec>
      <sec id="article-22122.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with Gaucher disease can present with several signs and symptoms, depending on the underlying type of disease. Commonly seen presenting signs and symptoms are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Painless&#x000a0;hepatomegaly&#x000a0;and&#x000a0;splenomegaly</p>
          </list-item>
          <list-item>
            <p>Hypersplenism&#x000a0;and&#x000a0;pancytopenia</p>
          </list-item>
          <list-item>
            <p>Severe joint pains, most frequently affecting the hips and knees</p>
          </list-item>
          <list-item>
            <p>Impaired olfaction and cognition (Type 1)</p>
          </list-item>
          <list-item>
            <p>Severe convulsions, hypertonia,&#x000a0;intellectual disability, and apnea (Type 2)</p>
          </list-item>
          <list-item>
            <p>Myoclonus, seizures, dementia, and ocular muscle apraxia (Type 3)</p>
          </list-item>
          <list-item>
            <p>Parkinsonism</p>
          </list-item>
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Yellowish-brown skin&#x000a0;pigmentation</p>
          </list-item>
        </list>
        <p>The diagnosis of Gaucher disease depends upon finding a low GBA1 enzyme level in peripheral blood leukocytes and establishing the presence of mutant alleles in the <italic toggle="yes">GBA1</italic> gene. Even though only a blood sample is needed to diagnose Gaucher disease, some patients undergo unnecessary invasive bone marrow or liver biopsy before making a correct diagnosis. Physician awareness of the signs and symptoms of Gaucher disease can help avoid such mishaps. Moreover, before an accurate diagnosis, many patients with an enlarged liver or spleen are told they could have cancer.<xref ref-type="bibr" rid="article-22122.r5">[5]</xref></p>
      </sec>
      <sec id="article-22122.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>
<bold>CBC Count</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CBC and platelet count will assess the degree of cytopenia.</p>
          </list-item>
        </list>
        <p>
<bold>Liver Function Enzyme Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild elevation of liver enzyme levels is common; the presence of jaundice or abnormal hepatocellular synthetic function merits further study.</p>
          </list-item>
        </list>
        <p>
<bold>Coagulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Regular monitoring should be performed.<xref ref-type="bibr" rid="article-22122.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Enzyme Activity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diagnosis is confirmed through measurement of glucocerebrosidase activity in peripheral blood leukocytes. Less than 15% of mean normal activity is diagnostic for Gaucher disease.</p>
          </list-item>
        </list>
        <p>
<bold>Genotype Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Molecular diagnosis is often helpful in Ashkenazi patients, in whom 6 <italic toggle="yes">GBA1</italic> mutations (<italic toggle="yes">c.84insG, L444P, N370S,&#x000a0; IVS2+1g&#x0003e;a, V394L, and R496H</italic>) account for most disease alleles.</p>
          </list-item>
          <list-item>
            <p>In some ethnicities, sequencing of the exons of <italic toggle="yes">GBA1</italic> may be necessary to establish the genotype.</p>
          </list-item>
          <list-item>
            <p>Mutation analysis has limited predictive value with respect to Gaucher disease progression. Avoid relying on PCR-based tests for individual mutations because they do not reveal the presence of recombinant alleles associated with greater disease severity.</p>
          </list-item>
        </list>
        <p>
<bold>Associated Marker Testing</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Angiotensin-converting enzyme, total acid phosphatase,&#x000a0;and ferritin levels are usually elevated. These levels may normalize with treatment.</p>
          </list-item>
          <list-item>
            <p>Monitoring chitotriosidase enzyme is useful except in the 10% of the population with a deficiency in this protein.</p>
          </list-item>
          <list-item>
            <p>Monitoring glucosylsphingosine&#x000a0;levels may be useful, as the level&#x000a0;has been shown to correlate with response to therapy.</p>
          </list-item>
        </list>
        <p>
<bold>Imaging</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ultrasonography may reveal abdominal organomegaly.</p>
          </list-item>
          <list-item>
            <p>MRI may be useful in revealing early skeletal involvement (avascular necrosis, spinal degradation, and degree of bone marrow infiltration).</p>
          </list-item>
          <list-item>
            <p>Radiography may reveal skeletal manifestations and pulmonary involvement.</p>
          </list-item>
          <list-item>
            <p>Dual-energy x-ray absorptiometry may evaluate osteopenia and bone crises.</p>
          </list-item>
          <list-item>
            <p>Echocardiograms help evaluate the possibility of pulmonary hypertension.</p>
          </list-item>
          <list-item>
            <p>In neuronopathic Gaucher disease, monitoring of EEG, brainstem-evoked potential, swallowing studies, and neuro-ophthalmologic evaluation should be done at regular intervals.</p>
          </list-item>
        </list>
        <p>
<bold>Bone Marrow Aspiration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In the past, the diagnosis was made by finding classic glycolipid-laden macrophages in bone marrow aspirate.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Today, bone marrow aspiration is not the initial diagnostic test because the blood enzyme test is more sensitive, specific, and less invasive.</p>
          </list-item>
        </list>
        <p>
<bold>Liver Biopsy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A liver biopsy may be performed to evaluate unexplained hepatomegaly. However, a biopsy is rarely necessary because a specific diagnostic test is available.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22122.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for Gaucher disease falls into&#x000a0;2 categories: enzyme replacement therapy and substrate reduction therapy.<xref ref-type="bibr" rid="article-22122.r7">[7]</xref>&#x000a0;In general,&#x000a0;enzyme replacement therapy&#x000a0;provides an intravenous infusion containing the enzyme that is deficient or absent in the body. In the case of Gaucher disease, this would be the GBA1 enzyme (also called beta-glucosylceramidase or beta-glucocerebrosidase). The FDA has approved Cerezyme (imiglucerase) and VPRIV (velaglucerase alfa) for Gaucher disease types 1 and 3&#x000a0;enzyme replacement therapy. Enzyme replacement therapy&#x000a0;typically cannot replace an enzyme deficient in the brain due to the blood-brain barrier and, therefore, is not effective for treating the central nervous system problems associated with types 2 and 3 Gaucher disease.&#x000a0;Enzyme replacement therapy&#x000a0;will help with the "non-brain" signs and symptoms associated with type 3 Gaucher disease, eg, enlarged organs and skeletal issues. Enzyme replacement therapy&#x000a0;does not correct the underlying genetic defect and only relieves signs, symptoms, and ongoing damage caused by the accumulation of toxins. Moreover, it is possible to develop antibodies to the replacement enzyme.<xref ref-type="bibr" rid="article-22122.r7">[7]</xref></p>
        <p>Substrate reduction therapy&#x000a0;is an orally administered small-molecule drug&#x000a0;(not protein) that relies on a strategy distinct from enzyme replacement therapy. In&#x000a0;substrate reduction therapy, the goal is to reduce substrate levels such that toxic accumulation of the substrate's subsequent degradative product is diminished to a clinically less toxic level. In the case of Gaucher disease, the goal is to use&#x000a0;substrate reduction therapies&#x000a0;to inhibit the first committed step in glycosphingolipid biosynthesis. There are&#x000a0;2 FDA-approved&#x000a0;substrate reduction therapy&#x000a0;drugs to treat patients with Gaucher disease: eliglustat and miglustat. Eliglustat, a glucosylceramide synthase inhibitor, is indicated only for type 1 Gaucher disease and does not effectively cross the blood-brain barrier.<xref ref-type="bibr" rid="article-22122.r8">[8]</xref>&#x000a0;It is not yet known if&#x000a0;eliglustat is safe or effective in children. Miglustat can cross the blood-brain barrier and potentially benefit types 2 and 3 Gaucher disease. Nevertheless, miglustat is currently indicated only for treating mild to moderate type 1 Gaucher disease in adults<xref ref-type="bibr" rid="article-22122.r7">[7]</xref>.</p>
        <p>Hematopoietic stem cell transplantation is another option for treating Gaucher's disease. However, with the advent of enzyme and substrate replacement therapies, it has fallen out of favor, given its association with high morbidity and mortality risk. Currently, it is still a definitive treatment option for patients with type 3 Gaucher's disease.<xref ref-type="bibr" rid="article-22122.r9">[9]</xref><xref ref-type="bibr" rid="article-22122.r10">[10]</xref><xref ref-type="bibr" rid="article-22122.r11">[11]</xref><xref ref-type="bibr" rid="article-22122.r12">[12]</xref><xref ref-type="bibr" rid="article-22122.r13">[13]</xref><xref ref-type="bibr" rid="article-22122.r14">[14]</xref></p>
        <p>Splenectomy&#x000a0;is rarely used nowadays but can be useful in patients with uncontrolled and serious thrombocytopenia or with severe, uncontrolled abdominal pain.<xref ref-type="bibr" rid="article-22122.r15">[15]</xref>&#x000a0;Patients undergoing splenectomy should be counseled regarding the higher risk of infections and vaccinated against encapsulated organisms as per institutional policies.&#x000a0;</p>
        <p>Future advancements in managing Gaucher disease will be looking to gene editing and gene therapy.<xref ref-type="bibr" rid="article-22122.r16">[16]</xref><xref ref-type="bibr" rid="article-22122.r17">[17]</xref></p>
      </sec>
      <sec id="article-22122.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis of Gaucher&#x000a0;disease includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
          <list-item>
            <p>Lewy body dementia</p>
          </list-item>
          <list-item>
            <p>Niemann-Pick disease</p>
          </list-item>
          <list-item>
            <p>Parkinson disease</p>
          </list-item>
          <list-item>
            <p>Sphingomyelinase deficiency&#x000a0;<xref ref-type="bibr" rid="article-22122.r18">[18]</xref><xref ref-type="bibr" rid="article-22122.r19">[19]</xref><xref ref-type="bibr" rid="article-22122.r20">[20]</xref><xref ref-type="bibr" rid="article-22122.r21">[21]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22122.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of Gaucher disease varies significantly depending on several factors, including the type of the disease, the age at which it is diagnosed, the promptness of treatment initiation, and the individual's overall health. Here's an overview of the prognosis for different types of Gaucher disease:</p>
        <p>
<bold>Type 1 Gaucher Disease (Non-Neuropathic)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with Type 1 Gaucher disease can have a near-normal life expectancy with appropriate treatment.</p>
          </list-item>
          <list-item>
            <p>Symptoms such as hepatosplenomegaly, anemia, and thrombocytopenia often improve with enzyme replacement therapy (ERT).</p>
          </list-item>
          <list-item>
            <p>Bone disease may progress more slowly or stabilize with ERT, but residual skeletal abnormalities can persist.<xref ref-type="bibr" rid="article-22122.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Type 2 Gaucher Disease (Acute Neuropathic Form):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 2 Gaucher disease is a severe and rapidly progressing form, primarily affecting infants.</p>
          </list-item>
          <list-item>
            <p>The prognosis for Type 2 is generally poor, with a significantly reduced life expectancy.</p>
          </list-item>
          <list-item>
            <p>Affected children often experience neurological decline and severe complications in infancy or early childhood.</p>
          </list-item>
        </list>
        <p>
<bold>Type 3 Gaucher Disease (Chronic Neuropathic Form):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 3 Gaucher disease is a milder form than Type 2, with a later onset of symptoms, typically in childhood or adolescence.</p>
          </list-item>
          <list-item>
            <p>Prognosis varies widely, with some individuals having a relatively stable course while others may experience more significant neurological involvement.</p>
          </list-item>
          <list-item>
            <p>Life expectancy is generally reduced compared to individuals with Type 1 Gaucher disease, but it is less severe than Type 2.</p>
          </list-item>
        </list>
        <p><bold>Perinatal Lethal Type Gaucher Disease&#x000a0; &#x000a0;</bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Perinatal lethal Gaucher disease is the most severe and rarest form of Gaucher disease.</p>
          </list-item>
          <list-item>
            <p>It is characterized by the earliest onset of symptoms, often before birth or in the neonatal period.</p>
          </list-item>
          <list-item>
            <p>The prognosis is extremely poor.</p>
          </list-item>
          <list-item>
            <p>Most individuals do not survive beyond infancy, and the condition is typically fatal shortly after birth.</p>
          </list-item>
          <list-item>
            <p>Due to the extreme severity of the disease, treatment options are limited, and enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) may not be effective.</p>
          </list-item>
          <list-item>
            <p>The focus of care for these infants is often on palliative measures to provide comfort and support during their short lives.<xref ref-type="bibr" rid="article-22122.r23">[23]</xref></p>
          </list-item>
        </list>
        <p><bold>Cardiovascular Type Gaucher Disease</bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular type Gaucher disease is an exceedingly rare and atypical variant of Gaucher disease.</p>
          </list-item>
          <list-item>
            <p>It primarily affects the cardiovascular system, leading to the deposition of glucocerebroside in the heart valves, arteries, and other vascular structures.</p>
          </list-item>
          <list-item>
            <p>The severity can vary widely among affected individuals. Some may have mild symptoms, while others experience more significant cardiac issues.</p>
          </list-item>
          <list-item>
            <p>The cardiac involvement may not respond as effectively to standard enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) as other forms of the disease.</p>
          </list-item>
          <list-item>
            <p>Prognosis can be influenced by the promptness of diagnosis, the extent of cardiac involvement, and the availability of specialized cardiac care.</p>
          </list-item>
        </list>
        <p>It is important to note that early diagnosis and timely initiation of treatment, particularly with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT), can significantly improve the prognosis for Gaucher disease patients.<xref ref-type="bibr" rid="article-22122.r7">[7]</xref> These treatments can alleviate many of the disease's symptoms, prevent complications, and improve overall quality of life.<xref ref-type="bibr" rid="article-22122.r24">[24]</xref></p>
      </sec>
      <sec id="article-22122.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of Gaucher disease stem from the progressive accumulation of glucocerebroside lipids within various organs and tissues. Among the most prevalent complications are skeletal manifestations, including osteopenia, osteoporosis, and pathological fractures, leading to chronic pain and impaired mobility. Hepatosplenomegaly, a common feature of the disease, may result in abdominal discomfort and an increased risk of bleeding and infection. Hematological complications such as anemia and thrombocytopenia can lead to fatigue and a heightened susceptibility to bruising and bleeding. Additionally, Gaucher disease may impact the lungs, causing interstitial lung disease, and can affect the central nervous system, leading to neurological complications in some cases. Understanding and managing these complications&#x000a0;are crucial to improving the quality of life for individuals with Gaucher disease.<xref ref-type="bibr" rid="article-22122.r25">[25]</xref></p>
      </sec>
      <sec id="article-22122.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education play pivotal roles in the management of Gaucher disease. Deterrence efforts primarily focus on genetic counseling and carrier screening within high-risk populations, such as Ashkenazi Jews, to inform individuals of their risk of carrying the disease-causing mutation and the potential for passing it to their offspring. Early identification of carriers can aid in informed family planning decisions.<xref ref-type="bibr" rid="article-22122.r1">[1]</xref></p>
        <p>Patient education is instrumental in empowering affected individuals with Gaucher disease and their families. Educating patients about the nature of the disease, its potential complications, available treatment options like enzyme replacement therapy and substrate reduction therapy, and the importance of regular monitoring fosters informed decision-making and adherence to therapy. Education can also help patients recognize the signs of disease progression or complications, promoting timely medical intervention and ultimately improving the overall prognosis and quality of life for those with Gaucher disease.<xref ref-type="bibr" rid="article-22122.r1">[1]</xref><xref ref-type="bibr" rid="article-22122.r26">[26]</xref></p>
        <p>Patients should also be made aware that researchers have established an&#x000a0;association between Gaucher disease and a slightly elevated risk of developing Parkinson disease later in life, a phenomenon also observed in carriers of Gaucher disease. For individuals with Gaucher disease, the risk of developing Parkinson disease by age 70 is approximately 5%,&#x000a0;increasing to approximately 8%&#x000a0;by age 80. Gaucher disease carriers face a risk of developing Parkinson disease by age 70 at about 3%, with a further slight increase observed by age 80.&#x000a0;Mutations in the <italic toggle="yes">GBA</italic> gene represent the most frequently identified genetic risk factor for Parkinson's disease.<xref ref-type="bibr" rid="article-22122.r27">[27]</xref><xref ref-type="bibr" rid="article-22122.r28">[28]</xref></p>
      </sec>
      <sec id="article-22122.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Enhancing patient-centered care and improving outcomes for Gaucher's disease, a complex lysosomal storage disorder, necessitates a multidisciplinary approach involving physicians, advanced care practitioners, nurses, pharmacists, and various healthcare professionals.</p>
        <p>Each healthcare team member should possess specialized knowledge and skills related to Gaucher disease, including understanding the genetic basis, clinical manifestations, diagnostic criteria, and treatment options. Physicians and advanced care practitioners may lead diagnosis and treatment, nurses monitor patient progress, and pharmacists manage medication regimens.&#x000a0;A&#x000a0;cohesive care plan encompasses all aspects of Gaucher disease management, including medical, psychological, and social needs.</p>
        <p>Each team member is crucial in ensuring patients receive comprehensive and effective care. Physicians often refer patients to specialists as needed.&#x000a0;Healthcare professionals should engage in continuing education activities to stay updated on advances in Gaucher disease management.&#x000a0;</p>
        <p>Gaucher disease management demands a collaborative and patient-centered approach that draws upon the expertise of various healthcare professionals. By fostering clearly defined roles and effective communication, an interprofessional&#x000a0;team provides optimal care and improves outcomes for individuals with this challenging condition.</p>
      </sec>
      <sec id="article-22122.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22122&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22122">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/gaucher-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22122">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22122/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22122">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22122.s16">
        <title>References</title>
        <ref id="article-22122.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stirnemann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belmatoug</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Camou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Serratrice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Froissart</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caillaud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levade</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Astudillo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Serratrice</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brassier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Billette de Villemeur</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.</article-title>
            <source>Int J Mol Sci</source>
            <year>2017</year>
            <month>Feb</month>
            <day>17</day>
            <volume>18</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">28218669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gahl</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Lysosomal storage diseases.</article-title>
            <source>Transl Sci Rare Dis</source>
            <year>2017</year>
            <month>May</month>
            <day>25</day>
            <volume>2</volume>
            <issue>1-2</issue>
            <fpage>1</fpage>
            <page-range>1-71</page-range>
            <pub-id pub-id-type="pmid">29152458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>181</fpage>
            <page-range>181-188</page-range>
            <pub-id pub-id-type="pmid">35867706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ka&#x00142;u&#x0017c;na</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trzeciak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ziemnicka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Machaczka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rucha&#x00142;a</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2019</year>
            <month>Dec</month>
            <day>02</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>275</fpage>
            <pub-id pub-id-type="pmid">31791361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giraldo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andrade-Campos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morales</surname>
                <given-names>M</given-names>
              </name>
              <collab>SEGA (SEguimiento del paciente de GAucher, Gaucher patient follow&#x02010;up) Group</collab>
            </person-group>
            <article-title>Recommendations on the follow-up of patients with Gaucher disease in Spain: Results from a Delphi survey.</article-title>
            <source>JIMD Rep</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-103</page-range>
            <pub-id pub-id-type="pmid">36636594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Castaman</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>24</day>
            <volume>11</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">36498496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mistry</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schiffmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Sidransky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Gaucher disease: Progress and ongoing challenges.</article-title>
            <source>Mol Genet Metab</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>120</volume>
            <issue>1-2</issue>
            <fpage>8</fpage>
            <page-range>8-21</page-range>
            <pub-id pub-id-type="pmid">27916601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mistry</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Lukina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ben Turkia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Baris</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghosn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Packman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pastores</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petakov</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Assouline</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balwani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Danda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hadjiev</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaemers</surname>
                <given-names>SJM</given-names>
              </name>
              <name>
                <surname>Tayag</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peterschmitt</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Outcomes after 18 months of eliglustat therapy in treatment-na&#x000ef;ve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.</article-title>
            <source>Am J Hematol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>92</volume>
            <issue>11</issue>
            <fpage>1170</fpage>
            <page-range>1170-1176</page-range>
            <pub-id pub-id-type="pmid">28762527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ringd&#x000e9;n</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Groth</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Erikson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Granqvist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sparrelid</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ten years' experience of bone marrow transplantation for Gaucher disease.</article-title>
            <source>Transplantation</source>
            <year>1995</year>
            <month>Mar</month>
            <day>27</day>
            <volume>59</volume>
            <issue>6</issue>
            <fpage>864</fpage>
            <page-range>864-70</page-range>
            <pub-id pub-id-type="pmid">7701581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erikson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Groth</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Percy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ringd&#x000e9;n</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Svennerholm</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type.</article-title>
            <source>Acta Paediatr Scand</source>
            <year>1990</year>
            <season>Jun-Jul</season>
            <volume>79</volume>
            <issue>6-7</issue>
            <fpage>680</fpage>
            <page-range>680-5</page-range>
            <pub-id pub-id-type="pmid">2386062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rappeport</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ginns</surname>
                <given-names>EI</given-names>
              </name>
            </person-group>
            <article-title>Bone-marrow transplantation in severe Gaucher's disease.</article-title>
            <source>N Engl J Med</source>
            <year>1984</year>
            <month>Jul</month>
            <day>12</day>
            <volume>311</volume>
            <issue>2</issue>
            <fpage>84</fpage>
            <page-range>84-8</page-range>
            <pub-id pub-id-type="pmid">6377066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chavananon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sripornsawan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Songthawee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chotsampancharoen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Gaucher Disease With Matched Sibling Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>e1153</fpage>
            <page-range>e1153-e1155</page-range>
            <pub-id pub-id-type="pmid">33661172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steward</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Jarisch</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Haemopoietic stem cell transplantation for genetic disorders.</article-title>
            <source>Arch Dis Child</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>12</issue>
            <fpage>1259</fpage>
            <page-range>1259-63</page-range>
            <pub-id pub-id-type="pmid">16301554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somaraju</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Tadepalli</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic stem cell transplantation for Gaucher disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Oct</month>
            <day>18</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD006974</fpage>
            <pub-id pub-id-type="pmid">29044482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schiffmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abrahamov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bar-Maor</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Guzzetta</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>NW</given-names>
              </name>
            </person-group>
            <article-title>Outcome of partial splenectomy for type I Gaucher disease.</article-title>
            <source>J Pediatr</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>126</volume>
            <issue>4</issue>
            <fpage>596</fpage>
            <page-range>596-7</page-range>
            <pub-id pub-id-type="pmid">7699540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daykin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sidransky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>1489</fpage>
            <page-range>1489-1503</page-range>
            <pub-id pub-id-type="pmid">33711910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enquist</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ooka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ehinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effective cell and gene therapy in a murine model of Gaucher disease.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2006</year>
            <month>Sep</month>
            <day>12</day>
            <volume>103</volume>
            <issue>37</issue>
            <fpage>13819</fpage>
            <page-range>13819-24</page-range>
            <pub-id pub-id-type="pmid">16954197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Rocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vici</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Burlina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venturelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fiumara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fecarotta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donati</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Spada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Concolino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pession</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>Jul</month>
            <day>21</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>197</fpage>
            <pub-id pub-id-type="pmid">37480063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boss&#x000f9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pedretti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bertolini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Gaucher Disease Presenting with Massive Splenomegaly and Hepatic Gaucheroma.</article-title>
            <source>Children (Basel)</source>
            <year>2023</year>
            <month>May</month>
            <day>12</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37238417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliva</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mechtler</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Sansen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keutzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prusa</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Streubel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease.</article-title>
            <source>Mol Genet Metab</source>
            <year>2023</year>
            <month>May</month>
            <volume>139</volume>
            <issue>1</issue>
            <fpage>107563</fpage>
            <pub-id pub-id-type="pmid">37086570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gar&#x000e7;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Correia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goulart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Gaucher Disease: One of the Few Causes of Massive Splenomegaly.</article-title>
            <source>Eur J Case Rep Intern Med</source>
            <year>2022</year>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>003705</fpage>
            <pub-id pub-id-type="pmid">36632535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Louw</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Giraldo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice.</article-title>
            <source>PLoS One</source>
            <year>2023</year>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>e0290401</fpage>
            <pub-id pub-id-type="pmid">37607165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chida</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suganami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Perinatal lethal Gaucher disease: A case report and review of literature.</article-title>
            <source>Brain Dev</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-139</page-range>
            <pub-id pub-id-type="pmid">36220738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Patient-reported outcomes in Gaucher's disease: a systematic review.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>Aug</month>
            <day>25</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>244</fpage>
            <pub-id pub-id-type="pmid">37626429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Changing clinical manifestations of Gaucher disease in Taiwan.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>Sep</month>
            <day>15</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>293</fpage>
            <pub-id pub-id-type="pmid">37715271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collin-Histed</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hopman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pacey</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Understanding patient and parent/caregiver perceptions on gene therapy in Gaucher disease: an international survey.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>Jan</month>
            <day>07</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <pub-id pub-id-type="pmid">36611195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilke</surname>
                <given-names>MVMB</given-names>
              </name>
              <name>
                <surname>Poswar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Borelli</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Michelin Tirelli</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Randon</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Pasetto</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Sebasti&#x000e3;o</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Iop</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Faqueti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kubaski</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schuh</surname>
                <given-names>AFS</given-names>
              </name>
              <name>
                <surname>Giugliani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>IVD</given-names>
              </name>
            </person-group>
            <article-title>Follow-up of pre-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2023</year>
            <month>Oct</month>
            <day>02</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>309</fpage>
            <pub-id pub-id-type="pmid">37784132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22122.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hertz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lichtenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haubenberger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tayebi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sidransky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease.</article-title>
            <source>J Mov Disord</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>321</fpage>
            <page-range>321-324</page-range>
            <pub-id pub-id-type="pmid">37309111</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
